Neutralizing anti-influenza A antibodies and uses thereof
Ebony Benjamin, Gaithersburg, MD (US); Nicole Kallewaard-LeLay, Gaithersburg, MD (US); Josephine Mary McAuliffe, Gaithersburg, MD (US); Frances Palmer-Hill, Gaithersburg, MD (US); Leslie Wachter, Gaithersburg, MD (US); Andy Yuan, Gaithersburg, MD (US); Qing Zhu, Gaithersburg, MD (US); Davide Corti, Bellinzona (CH); Antonio Lanzavecchia, Bellinzona (CH); Barbara Guarino, Bellinzona (CH); and Anna DeMarco, Bellinzona (CH)
Assigned to MEDIMMUNE, LLC, Gaithersburg, MD (US); and HUMABS BIOMED SA, Bellinzona (CH)
Filed by MEDIMMUNE, LLC, Gaithersburg, MD (US); and HUMABS BIOMED SA, Bellinzona (CH)
Filed on Oct. 21, 2021, as Appl. No. 17/507,482.
Application 17/507,482 is a division of application No. 16/596,039, filed on Oct. 8, 2019, granted, now 11,186,627.
Application 16/596,039 is a division of application No. 15/026,276, granted, now 10,494,419, issued on Dec. 3, 2019, previously published as PCT/US2014/058652, filed on Oct. 1, 2014.
Claims priority of provisional application 62/002,414, filed on May 23, 2014.
Claims priority of provisional application 61/885,808, filed on Oct. 2, 2013.
Prior Publication US 2022/0033480 A1, Feb. 3, 2022
1. An isolated antibody or a binding fragment thereof that is capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus, wherein the antibody or fragment thereof includes a set of six CDRs: HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 in which the set of six CDRs comprises the HCDR1 of SEQ ID NO.: 103, the HCDR2 of SEQ ID NO.: 104, the HCDR3 of SEQ ID NO.: 105, the LCDR1 of SEQ ID NO.: 108, the LCDR2 of SEQ ID NO.: 109 and-the LCDR3 of SEQ ID NO.: 110.